ALMIRALL S.A.

Almirall S.A. in Singapore is a trading company.

Almirall S.A. is a global pharmaceutical company headquartered in Spain, specializing in medical dermatology and dedicated to providing innovative solutions for skin health. Its presence in Singapore operates as a commercial affiliate, primarily focused on the sales, marketing, and distribution of its pharmaceutical products within the Singaporean market and potentially the broader Southeast Asian region. This entity functions as a commercial office responsible for market access, regulatory affairs, and promoting Almirall's specialized treatments to healthcare professionals and patients. It is not a manufacturing plant or factory.

Almirall S.A. Singapore Branch focuses on the commercialization of dermatological and therapeutic products. Their portfolio includes:

Therapeutic Areas and Key Products:

Medical Dermatology:

Klisyri (tirbanibulin): Treatment for actinic keratosis.

Wynzora (calcipotriene and betamethasone dipropionate): Treatment for plaque psoriasis.

Siliq (brodalumab): Treatment for moderate-to-severe plaque psoriasis.

General Dermatology:

Efracea (doxycycline): Treatment for inflammatory lesions of rosacea.

Solaraze (diclofenac sodium): Treatment for actinic keratosis.

Actikerall (fluorouracil and salicylic acid): Treatment for actinic keratosis.

Aesthetic Medicine:

Restylane family: A range of hyaluronic acid dermal fillers for facial rejuvenation.

Sculptra: A poly-L-lactic acid injectable for collagen stimulation.

Please note that product availability in Singapore may be subject to local regulatory approvals and specific distribution agreements.